Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics.
Reed
Carol
C
Kalnik
Matthew
M
Rakin
Kevin
K
Athanasiou
Maria
M
Judson
Richard
R
D000928:Antidepressive Agents / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D015195:Drug Design; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends
D000928:Antidepressive Agents